This page is continually updated with the latest news relating to the public health and legal issues arising from the revelation that Actos is tied with an increased risk of bladder cancer in patients. This is a subpage to our main Actos Bladder Cancer Lawyers page. You may also be interested in our Actos Side Effect Frequently Asked Questions page and my article (written for other lawyers) about the lawyer advertising for Actos lawsuits.

December 29, 2011: The United States Judicial Panel on Multidistrict Litigation consolidated all pre-trial proceedings in federal Actos lawsuits in the Western District of Louisiana. Actos lawsuits filed in Illinois, Missouri, and California, however, where Takeda has subsidiaries, will likely stay in those state courts.

December 1, 2011: A panel of federal judges held a hearing to decide where pre-trial proceedings for the Actos litigation should proceed. Bloomberg News reported on the hearing, at which lawyers for Takeda argued the Actos suits should be consolidated in federal court before Judge James Zagel in Chicago or before Judge Rebecca Doherty in Lafayette, Louisiana. Lawyers for patients injured by Actos argued for the cases to be consolidated before Judge Daniel Polster in Cleveland, or in the federal court in Birmingham, Alabama.

November 4, 2011: Takeda Pharmaceuticals, the maker of Actos, cut its forecasted profit for the year by 31 percent, citing a 13 percent drop in Actos sales in the first half of 2011. Given that the FDA warning did not come out until June, and the EMA warning did not come out until July, it seems likely that Actos sales will fall further in the second half of 2011.

October 21, 2011: The European Medicines Agency has updated its opinion on pioglitazone-containing anti-diabetes medicines such as Actos, concluding for the time being that “Pioglitazone remains a valid treatment option for certain patients with type 2 diabetes, but only when certain other treatments (metformin) have not been suitable or have failed to work adequately.”

October 18, 2011: The United States Judicial Panel on Multidistrict Litigation has ordered there be a hearing for December 1, 2011, to discuss the petition in MDL No. 2299, In re: Actos Product Liability Litigation, to discuss the plaintiffs’ motion for centralization of Actos cases in the United States District Court for the Southern District of Illinois. Takeda Pharmaceuticals responded to the motion agreeing that consolidation was acceptable, but arguing primarily in favor of the Northern District of Illinois instead. Here is Takeda’s response and the Plaintiffs’ reply.